Lanean...

Updated Results of Rituximab Pre- and Post-BEAM with or without (90)Yttrium-Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-Cell Lymphoma

PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ((90)YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Chahoud, Jad, Sui, Dawen, Erwin, William D., Gulbis, Alison M., Korbling, Martin, Zhang, Mingzhi, Ahmed, Sairah, Alatrash, Gheath, Anderlini, Paolo, Ciurea, Stefan O., Oran, Betul, Fayad, Luis E., Bassett, Roland L., Jabbour, Elias J., Medeiros, L. Jeffrey, Macapinlac, Homer A., Young, Ken H., Khouri, Issa F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955837/
https://ncbi.nlm.nih.gov/pubmed/29476021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3561
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!